Results 151 to 160 of about 567,668 (313)

Agonist and Antagonist Effects of Aripiprazole on D2-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone [PDF]

, 2014
G. F., N. Raivio, Josefa Sabrià, Jordí Ortiz   +3 more
openalex   +1 more source

Gender differences in dopamine partial agonists treatment in schizophrenia: a longitudinal 18 month naturalistic follow-up with cariprazine

, 2023
Claudia Carmassi, Virginia Pedrinelli, S. Fantasia, Davide Gravina, Leonardo Massoni, Valerio Dell’Oste, Carlo Antonio Bertelloni, L. Dell’Osso   +7 more
openalex   +1 more source

The multifunctional dopamine D2/D3 receptor agonists also possess inhibitory activity against the full-length tau441 protein aggregation [PDF]

, 2020
Iva Ziu, Irving D. Rettig, Dan Luo, Aloke K. Dutta, Theresa M. McCormick, Colin G. Wu, Sanela Martić   +6 more
openalex   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Prolactin secreting pituitary neuroendocrine tumors treated by dopamine agonists: predictors of response. [PDF]

Front Endocrinol (Lausanne)
Mele C, Zavattaro M, Pitino R, Romanisio M, Ferrero A, Sturnia S, Catenazzi S, Rosmini F, Baldi S, Marzullo P, Aimaretti G, Prodam F, Caputo M.   +12 more
europepmc   +1 more source

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. [PDF]

Front Endocrinol (Lausanne), 2021
Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB.   +5 more
europepmc   +1 more source

Dopamine Agonist [PDF]

, 2020
openaire   +1 more source

Conclusion lessons from the novel D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications

, 2003
P. M. A. Calverley, E.T. Keating, Mitch Goldman, Frank E. Casty   +3 more
openalex   +1 more source

The dopamine D2/D3 receptor agonist quinpirole increases checking-like behaviour in an operant observing response task with uncertain reinforcement: A novel possible model of OCD [PDF]

, 2014
Dawn M. Eagle, Cristie Noschang, Laure-Sophie Camilla d’Angelo, C Noble, Jacob Day, Marie Louise Dongelmans, David Theobald, Adam C. Mar, Gonzalo P. Urcelay, Sharon Morein‐Zamir, Trevor W. Robbins   +10 more
openalex   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source